MicroRNA-1271 inhibits the progression of papillary thyroid carcinoma by targeting IRS1 and inactivating AKT pathway

Y. Chen, S.-A. Hao, Y. Jiang, B. Gao, W.-G. Tian, S. Zhang, L.-J. Guo, L.-L. Wang, D.-L. Luo

Department of Breast, Thyroid Surgery, Research Institute of Surgery, Daping Hospital, Army Military Medical University, Chongqing, China. luodl968@163.com

---

• Oncology

OBJECTIVE: The important role of microRNA-1271 (miR-1271) has been identified in human diseases and cancers. However, the biological function of miR-1271 remains ambiguous in papillary thyroid carcinoma (PTC). Therefore, the specific role of miR-1271 was investigated in PTC.
PATIENTS AND METHODS: The expressions of miR-1271 and insulin receptor substrate 1 (IRS1) were detected by quantitative Real Time-Polymerase Chain Reaction (qRT-PCR) assay. The protein expression of the genes was measured by Western blot analysis. The function of miR-1271 was investigated using methyl thiazolyl tetrazolium (MTT) and transwell assays. The Dual-Luciferase assay was used to observe the relationship between miR-1271 and IRS1.
RESULTS: MiR-1271 was downregulated in PTC tissues. Moreover, overexpression of miR-1271 suppressed migration, invasion and proliferation of PTC cells. Furthermore, IRS1 was indicated as a direct target gene of miR-1271 and knockdown of IRS1 inhibited cell migration, invasion and proliferation in PTC. In addition, miR-1271 inhibited the progression of PTC by targeting IRS1. Besides that, miR-1271 blocked the epithelial-mesenchymal transition (EMT) and protein kinase B (AKT) pathway in PTC.
CONCLUSIONS: MiR-1271 inhibited the progression of PTC by targeting IRS1 and blocking EMT and AKT pathway.

Free PDF Download